Dual-Pathway Modulation for Neutrophil Migration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively address neutrophil-mediated inflammation, particularly in chronic inflammatory diseases, as they do not adequately modulate the pro-inflammatory MRP2/HXA3 pathway and anti-inflammatory P-gp/endocannabinoid pathway, leading to excessive neutrophil migration and tissue damage.
Innovation Solution
Administering therapeutically effective amounts of compounds that inhibit MRP2 and HXA3 synthase, increase N-acylethanolamines, and enhance MRP1 levels to reduce neutrophil migration into target tissues, thereby modulating the MRP2/HXA3 and P-gp/endocannabinoid pathways to mitigate inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If MRP2 and HXA3 synthase are inhibited, then neutrophil migration is reduced, but inflammation control is insufficient without modulating anti-inflammatory pathways
Solution Approach 1:
The patent divides the inflammation treatment into two separate pathway modulations: (1) inhibition of pro-inflammatory MRP2/HXA3 pathway to reduce neutrophil recruitment, and (2) enhancement of anti-inflammatory P-gp/endocannabinoid pathway to promote resolution. This segmentation allows targeted control of different inflammatory phases without interference.
Solution Approach 2:
The patent combines two complementary therapeutic approaches into a unified treatment strategy: using MRP2 inhibitors (e.g., probenecid) to block pro-inflammatory signaling while simultaneously using P-gp substrates or endocannabinoid modulators to enhance anti-inflammatory signaling. This merging creates synergistic anti-inflammatory effects.
2Reliability
If P-gp levels are increased to enhance anti-inflammatory effects, then neutrophil migration is reduced, but pathway balance is disrupted without MRP2 inhibition
Solution Approach 1:
The patent applies preliminary anti-action by first inhibiting MRP2 to prevent pro-inflammatory HXA3-mediated neutrophil recruitment before enhancing P-gp activity. This preemptive blockade of the pro-inflammatory pathway ensures that subsequent anti-inflammatory actions occur in a permissive environment without counteracting pro-inflammatory signals.
Solution Approach 2:
The patent uses endocannabinoids (anandamide, 2-AG) as intermediary molecules that are substrates for P-gp. These endocannabinoids mediate the anti-inflammatory effects by activating CB2 receptors on neutrophils and other immune cells, providing a biochemical bridge between P-gp transport activity and anti-inflammatory signaling outcomes.
3Productivity
If MRP2 activity is enhanced to transport HXA3, then pro-inflammatory signaling is increased, but neutrophil migration becomes excessive causing tissue damage
Solution Approach 1:
The patent converts the harmful effect of excessive HXA3 transport into a beneficial outcome by using MRP2 inhibitors to block this pathway. By inhibiting MRP2, the patent prevents the formation of excessive HXA3 concentration gradients that would otherwise drive pathological neutrophil migration and tissue damage, thereby transforming a potentially harmful transport function into a therapeutic target.
Data Source
AI summary
Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.